Radnor, Pennsylvania–(business wire)–Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) is a pharmaceutical company dedicated to developing innovative therapies to treat seizure disorders, whose board of directors includes CEO and Director announced the appointment of Scott Braunstein. MD, Chairman of the Board. Dr. Braunstein will succeed Nicole Vituro, who has retired from the Board following his 17-year tenure, which includes the last three years as Chairman.
Marinus also announced two resignations from the board of directors, Michael Dougherty, who retired, and Santiago Arroyo, M.D., who resigned following the announcement of his appointment as Chief Medical Officer of Biotechnology, based in Cambridge, Massachusetts. Announced. Company. The Board has launched a search for replacements for these directors.
Tim M. Maryven, newly appointed Lead Independent Director of Marinus, said: US Approval and Early Commercial Launch of ZTALMY® (ganaxolone), and his ability to articulate and execute on a long-term strategic vision that includes a strong clinical pipeline for Marinus. On behalf of the Board, I would like to thank Nicole for her unwavering dedication to Marinus over the years and for the many milestones she has achieved during his tenure, and to acknowledge and thank Michael and Santiago for their many contributions. I think. I look forward to complementing the Board’s skills and expertise with new members to support Marinus’ efforts to scale. ”
Chairman and CEO Scott Braunstein said: “I am grateful for the continued support of our major shareholders for our program in this transition and am encouraged by the progress achieved to date in executing our strategy. We believe we can strengthen our commitment to improving the lives of patients with seizure disorders based on We have a chance to let go.”
Dr. Braunstein has been CEO of Marinus since August 2019 and brings nearly 30 years of diverse biopharmaceutical expertise. Most recently, Scott served as Chief Strategy Officer and Chief Operating Officer at Pacira Biosciences, Inc. Prior to that, he spent 13 years at JP Morgan as a Portfolio Manager for the Global Healthcare Fund and as a Healthcare Analyst for the U.S. and Global Equities He team. Dr. Braunstein has served on the boards of several public biotechnology companies for nearly 10 years, and currently serves on the boards of Trevena, Inc. and Caribou Biosciences, Inc. Albert He has worked as a clinical assistant professor at the Einstein College of Medicine and Columbia University Medical Center.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to developing innovative treatments for seizure disorders. The company’s commercial product ZTALMY® (Ganaxolone) Oral Suspension CV is approved by the US Food and Drug Administration for the treatment of seizures associated with CDKL5 deficiency in patients 2 years of age and older. Ganaxolone’s potential is also being investigated in other rare seizure disorders, including phase 3 trials in tuberous sclerosis and refractory status epilepticus. Ganaxolone is a neuroactive steroid GABA.a Receptor modulators acting on well-characterized targets in the brain known to have anti-seizure effects. Developed in IV and oral formulations to maximize therapeutic coverage for adult and pediatric patients in acute and chronic care settings. For more information, please visit www.marinuspharma.com.
Forward-Looking Statements
The statements contained in this press release, to the extent that they are not statements of historical fact regarding Marinus, are forward-looking statements that reflect management’s current beliefs and expectations made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This is a description about Words such as “may,” “would,” “expect,” “anticipate,” “estimate,” “intend,” “believe,” and similar expressions (and future events, circumstances, or other words or expressions referring to circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among other things, statements regarding ZTALMY’s commercialization plans. Statements regarding anticipated clinical development plans, clinical trial enrollment, ganaxolone regulatory communications and submissions, and timing. statements regarding future commercial opportunities for ganaxolone; and other statements regarding the company’s future operations, financial performance, financial condition, prospects, objectives and other future events.
The forward-looking statements in this press release involve material risks that our clinical development programs, future results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements. and uncertainties. Such risks and uncertainties include, among other things, the uncertainty regarding the impact of these governance changes on our business. Unexpected market acceptance, payer coverage or future prescriptions and revenue generated by ZTALMY. unanticipated action by the FDA or other regulatory agencies regarding our products; Uncertainties and delays related to competing conditions and unanticipated adverse events or patient outcomes from treatment with ZTALMY, clinical trial design, enrollment, completion, and results. Unforeseen costs and expenses. different interpretations of clinical data; our ability to comply with the FDA’s requirement to conduct additional post-market surveillance within the required timeframe; the timing of our other product candidate submissions to regulatory authorities; regulatory agencies, including the FDA and EMA, may not grant or delay approval of our product candidates; Early clinical trials may not be indicative of results of later clinical trials. Clinical trial results may not support, or not support at all, regulatory approval or further development in specific indications. FDA’s or EMA’s actions or advice may affect the design, initiation, timing, continuation and/or progression of clinical trials or may result in the need for additional clinical trials. our ability to obtain and maintain regulatory approval for our product candidates; our ability to develop new formulations of ganaxolone or prodrugs; our ability to obtain, maintain, protect and defend our product candidate intellectual property; potential adverse effects of third party patents on our ability or our collaborators’ ability to commercialize ganaxolone; delays, interruptions or failures in the manufacture and supply of our product candidates; Market size and growth potential for the Company’s product candidates and the Company’s ability to serve those markets; The Company’s cash and cash equivalents may not be sufficient to support its business plans for as long as anticipated. Company’s expectations, projections and estimates regarding expenses, future earnings, capital requirements and potential and need for additional financing. The Company’s ability to raise additional funding to support clinical development and commercial programs. Former US Partners may breach their obligations under their respective agreements with us or terminate such agreements in accordance with their respective terms. the risk that pharmaceutical quality requirements will not support ongoing clinical investigation of our product candidates, leading to delays or termination of such clinical trials and product approvals; The impact of the COVID-19 pandemic on our businesses, the healthcare community, regulators and the global economy. The availability or potential availability of alternative products or treatments for conditions targeted by us, which may affect the availability or commercial potential of our product candidates. This list is not exhaustive and these and other risks are disclosed in our periodic reports, including our Annual Report on Form 10-K, Quarterly Report on Form 10-Q and Current Report on Form 8-K. listed and filed or provided to a brokerage firm. and Exchange Commission, available at www.sec.gov. Forward-looking statements in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
